• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Financial Officer Grasman Jeroen Nicolaas was granted 350,000 shares (SEC Form 4)

    5/20/25 10:45:14 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VXRT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Grasman Jeroen Nicolaas

    (Last) (First) (Middle)
    C/O VAXART, INC.
    170 HARBOR WAY, SUITE 300

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Vaxart, Inc. [ VXRT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    05/19/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/19/2025 A 350,000(1) A $0 350,000 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $0.4998 05/19/2025 A 1,000,000 (2) 05/19/2035 Common Stock 1,000,000 $0 1,000,000 D
    Explanation of Responses:
    1. Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the vesting commencement date of May 19, 2025, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date.
    2. The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on May 19, 2026, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on May 19, 2029.
    /s/ Edward Berg, Attorney-in-Fact for Jeroen Grasman 05/20/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VXRT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VXRT

    DatePrice TargetRatingAnalyst
    8/15/2024$4.00Outperform
    Oppenheimer
    12/29/2021$13.00 → $12.00Buy
    Jefferies
    11/2/2021$15.00Overweight
    Cantor Fitzgerald
    6/30/2021$13.00 → $9.00Buy → Neutral
    B. Riley Securities
    6/29/2021$13.00 → $9.00Buy → Neutral
    B. Riley Securities
    6/24/2021$13.00Buy
    Jefferies
    More analyst ratings

    $VXRT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, Chief Exec Officer Lo Steven bought $49,000 worth of shares (100,000 units at $0.49) (SEC Form 4)

      4 - Vaxart, Inc. (0000072444) (Issuer)

      5/19/25 6:49:39 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Watson W. Mark bought $13,578 worth of shares (20,000 units at $0.68), increasing direct ownership by 34% to 78,125 units (SEC Form 4)

      4 - Vaxart, Inc. (0000072444) (Issuer)

      6/20/24 6:10:10 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Vaxart Inc

      DEFA14A - Vaxart, Inc. (0000072444) (Filer)

      5/16/25 8:30:40 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Vaxart, Inc. (0000072444) (Filer)

      5/16/25 8:30:10 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Vaxart Inc

      DEFA14A - Vaxart, Inc. (0000072444) (Filer)

      5/16/25 7:45:18 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced that the Compensation Committee of the Board of Directors approved certain equity awards to the Company's new Chief Financial Officer, Jeroen Grasman, effective May 19, 2025. The awards were made pursuant to the Company's previously disclosed offer letter with Mr. Grasman, and as a material inducement to his joining the Company as Chief Financial Officer. The awards made to Mr. Grasman are as follows: (i) an option to purchase 1,000,000 shares of Vaxart's common stock, which vests as to 1/4th of the total shares on the one-year anniversary of his start date,

      5/20/25 5:00:17 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting

      Company Urges Stockholders to Vote ‘FOR' Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced that it has filed a supplement to its proxy statement for its Annual Meeting. The board of directors approved the following two items, if Proposal #2 passes: The current authorized number of shares of the Company's common stock would be proportionally reduced in line with the reverse stock split ratio, to be approved by stockholders at a future special meeting of stockholders that

      5/16/25 8:00:00 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

      SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), to initiate dosing in the 10,000-participant portion of its ongoing Phase 2b clinical trial evaluating its oral pill COVID-19 vaccine candidate. "We are pleased to receive BARDA approval to move forward with dosing in this large-scale study and expect to dose the first patient in this cohort in the second quarter of 2025," said Steven Lo, Chief Executive

      5/15/25 8:00:00 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Vaxart Inc (Amendment)

      SC 13G/A - Vaxart, Inc. (0000072444) (Subject)

      2/13/24 5:16:04 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Vaxart Inc

      SC 13G - Vaxart, Inc. (0000072444) (Subject)

      1/19/24 4:30:58 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Vaxart Inc

      SC 13G - Vaxart, Inc. (0000072444) (Subject)

      2/9/23 11:35:17 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Leadership Updates

    Live Leadership Updates

    See more
    • Vaxart Appoints Jeroen Grasman as Chief Financial Officer

      - Mr. Grasman brings over two decades of biotech financial leadership experience - SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced the appointment of Jeroen Grasman as its Chief Financial Officer (CFO), effective May 19, 2025. Mr. Grasman succeeds Phillip Lee, who is resigning from his position as CFO for personal reasons. To ensure a smooth transition, Mr. Lee will remain with the Company as a non-executive employee through June 1, 2025. "We are delighted to welcome Jeroen to the Vaxart team," said Steven Lo, Chief Executive Officer of Vaxart. "His extensive financial expertise and proven track record in the biotech sector, includ

      5/13/25 4:01:00 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors

      Mr. Finney brings 35 years of leadership, operations and corporate development experience SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced the appointment of Kevin Finney to the Company's Board of Directors, effective today. Mr. Finney is a seasoned healthcare executive and experienced board member who brings decades of industry leadership experience and operational expertise. Mr. Finney will serve as a member of the Audit and Nominating and Governance Committees of the Board. "Kevin adds a wealth of healthcare industry experience spanning executive leadership, governance, operations, and corporate deve

      1/28/25 8:00:00 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

      Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced that it has appointed Steven Lo as President and Chief Executive Officer and a member of the Board of Directors, effective as of March 18, 2024. Mr. Lo is a highly experienced biopharma executive with over 25 years of experience in the healthcare, biotechnology, and pharmaceutical industries, including over 12 years of C-level experience in publicly traded biotech companies. Michael J. Finney, Ph.D. will step down as interim Chief Executive Officer and will continue to serve as Ch

      3/6/24 8:00:00 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Vaxart with a new price target

      Oppenheimer initiated coverage of Vaxart with a rating of Outperform and set a new price target of $4.00

      8/15/24 7:45:56 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies resumed coverage on Vaxart with a new price target

      Jefferies resumed coverage of Vaxart with a rating of Buy and set a new price target of $12.00 from $13.00 previously

      12/29/21 7:23:57 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Vaxart with a new price target

      Cantor Fitzgerald initiated coverage of Vaxart with a rating of Overweight and set a new price target of $15.00

      11/2/21 7:42:45 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Financials

    Live finance-specific insights

    See more
    • Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

      Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company's second-generation oral norovirus vaccine constructs, with topline data expected in mid-2025 New avian influenza vaccine candidate was 100% protective in a ferret challenge model, compared with 0% survival in placebo-treated animals Jeroen Grasman appointed as Chief Financial Officer effective May 19, 2025 Cash, cash equivalents and investments of $41.9 million as of March 31, 2025; Current runway into 2026 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 13, 2025 (

      5/13/25 4:05:00 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13

      Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Tuesday, May 13, 2025 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13753354 Investors may submit written questions in advance of the confer

      5/2/25 8:00:00 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

      Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025 Continues per protocol follow-up for the COVID-19 Phase 2b 400-person sentinel cohort Cash, cash equivalents and investments of $51.7 million as of December 31, 2024 provides runway through multiple development milestones and into the fourth quarter of 2025 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the full year 2024. "Since our founding, Vaxart has been on a mission to transform glo

      3/20/25 4:01:00 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Grasman Jeroen Nicolaas was granted 350,000 shares (SEC Form 4)

      4 - Vaxart, Inc. (0000072444) (Issuer)

      5/20/25 10:45:14 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Grasman Jeroen Nicolaas

      3 - Vaxart, Inc. (0000072444) (Issuer)

      5/20/25 10:43:43 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President, Chief Exec Officer Lo Steven bought $49,000 worth of shares (100,000 units at $0.49) (SEC Form 4)

      4 - Vaxart, Inc. (0000072444) (Issuer)

      5/19/25 6:49:39 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care